Novel Therapies for Type 2 Diabetes Mellitus / 대한소아내분비학회지
Journal of Korean Society of Pediatric Endocrinology
;
: 11-18, 2009.
Article
Dans Coréen
| WPRIM
| ID: wpr-198308
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination of insulin resistance and betacell dysfunction. The role of new hormones and systems in maintaining blood glucose homeostasis has recently been recognized. This recognition has led to the development of several novel classes of medications, including the incretin mimetic agents (glucagon like polypeptide-1 analogs and dipeptidyl peptidase IV inhibitors), the amylin analog and the endocannabinoid-1 receptor blocker. This review looks at these new agents in terms of their mode of action, pharmacokinetics and use in clinical practice. The new agents offer treatment options in select adult patients now, however, the efficacy and the safety has to be evaluated thoroughly by long term studies before the application to pediatric patients.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Glycémie
/
Insulinorésistance
/
Dipeptidyl peptidase 4
/
Diabète
/
Diabète de type 2
/
Peptides glucagon-like
/
Inhibiteurs de la dipeptidyl-peptidase IV
/
Incrétines
/
Polypeptide amyloïde des ilots
/
Homéostasie
Limites du sujet:
Adulte
/
Humains
langue:
Coréen
Texte intégral:
Journal of Korean Society of Pediatric Endocrinology
Année:
2009
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS